Hoth Therapeutics' Investigational Cancer Drug Shows Encouraging Preclinical Activity In Stomach Cancers
Portfolio Pulse from Vandana Singh
Hoth Therapeutics Inc (NASDAQ:HOTH) announced encouraging preclinical results for its investigational cancer drug, HT-KIT. The drug, initially developed for systemic mastocytosis, showed potential applications in gastrointestinal stromal tumors and acute myeloid leukemia. Despite an initial 9% increase, HOTH's stock price fell 23.90% to $2.74.
September 13, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Hoth Therapeutics' stock price fell 23.90% despite positive preclinical results for its investigational cancer drug, HT-KIT.
The positive preclinical results for HT-KIT initially led to a 9% increase in HOTH's stock price. However, the stock price fell 23.90% later, indicating that despite the positive news, market sentiment towards HOTH is negative in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100